Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xingming Zhang

Showing results (71-80 of 121) with videos related to

Pageof 13
Sort By:
Scientific Reports|March 25, 2016
Different lasers in the treatment of benign prostatic hyperplasia: a network meta-analysisXingming Zhang, Pengfei Shen, Qiying He, et al.
Oncology Research|July 7, 2023
Mutations in epigenetic regulator <i>KMT2C</i> detected by liquid biopsy are associated with worse survival in prostate cancer patientsSha Zhu, Nanwei Xu, Jiayu Liang, et al.
Urologic Oncology|October 15, 2018
What kind of patients with castration-naïve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysisGuangxi Sun, Xingming Zhang, Junru Chen, et al.
American Journal of Translational Research|October 12, 2020
Assessment for prognostic value of differentially expressed genes in immune microenvironment of clear cell renal cell carcinomaXiaoxue Yin, Xingming Zhang, Zhenhua Liu, et al.
BMC Cancer|April 18, 2019
Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinomaXingming Zhang, Xiaoxue Yin, Haoran Zhang, et al.
Japanese Journal of Clinical Oncology|July 29, 2020
The influence of dynamic changes in lipid metabolism on survival outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitorsXingming Zhang, Haoran Zhang, Jindong Dai, et al.
Cancer Treatment Reviews|June 21, 2024
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysisYaowen Zhang, Junru Chen, Haoyang Liu, et al.
The Prostate|March 4, 2025
The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone AcetateYifu Shi, Xinyuan Wei, Fengnian Zhao, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 14, 2023
AKR1B10 Is a New Sensitive and Specific Marker for Fumarate Hydratase-Deficient Renal Cell CarcinomaLinmao Zheng, Xingming Zhang, Xiuyi Pan, et al.
Cancer Management and Research|September 13, 2021
Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell CarcinomaXudong Zhu, Xingming Zhang, Guangxi Sun, et al.
Pageof 13

Showing results (71-80 of 121) with videos related to

Sort By:
Pageof 13
Scientific Reports|March 25, 2016
Different lasers in the treatment of benign prostatic hyperplasia: a network meta-analysisXingming Zhang, Pengfei Shen, Qiying He, et al.
Oncology Research|July 7, 2023
Mutations in epigenetic regulator <i>KMT2C</i> detected by liquid biopsy are associated with worse survival in prostate cancer patientsSha Zhu, Nanwei Xu, Jiayu Liang, et al.
Urologic Oncology|October 15, 2018
What kind of patients with castration-naïve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysisGuangxi Sun, Xingming Zhang, Junru Chen, et al.
American Journal of Translational Research|October 12, 2020
Assessment for prognostic value of differentially expressed genes in immune microenvironment of clear cell renal cell carcinomaXiaoxue Yin, Xingming Zhang, Zhenhua Liu, et al.
BMC Cancer|April 18, 2019
Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinomaXingming Zhang, Xiaoxue Yin, Haoran Zhang, et al.
Japanese Journal of Clinical Oncology|July 29, 2020
The influence of dynamic changes in lipid metabolism on survival outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitorsXingming Zhang, Haoran Zhang, Jindong Dai, et al.
Cancer Treatment Reviews|June 21, 2024
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysisYaowen Zhang, Junru Chen, Haoyang Liu, et al.
The Prostate|March 4, 2025
The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone AcetateYifu Shi, Xinyuan Wei, Fengnian Zhao, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 14, 2023
AKR1B10 Is a New Sensitive and Specific Marker for Fumarate Hydratase-Deficient Renal Cell CarcinomaLinmao Zheng, Xingming Zhang, Xiuyi Pan, et al.
Cancer Management and Research|September 13, 2021
Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell CarcinomaXudong Zhu, Xingming Zhang, Guangxi Sun, et al.
Pageof 13